{"prompt": "['may interfere with the interpretation of study results and, in the judgment of the investigator,', 'would make the patient inappropriate for entry into this study.', '16. Avelumab treatment contraindications:', 'a. Hypersensitivity to the active ingredient or to any excipient.', 'b. Inadequate bone marrow function: WBC <2900 mm3 and/or HCT <30% and/or', 'platelets count <90000 mm3.', 'c. Uncontrolled serous effusions (pleural, pericardic or peritoneal)', 'd. Blood Pressure <60 mmHg.', 'e. Pregnancy or breast feeding.', 'f.', 'Active infections.', 'Known history of testing positive for HIV or known acquired immunodeficiency', 'syndrome.', 'g. Brain metastases.', 'h. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular', 'accident/stroke (< 6 months prior to enrollment), myocardial infarction K 6 months', 'prior to enrollment), unstable angina, congestive heart failure @> New York Heart', 'Association Classification Class II), or serious cardiac arrhythmia requiring', 'medication.', '17. Participation to other concomitant experimental study.', '6.0 PROTOCOL PROCEDURES', '6.1 Drug administration', 'Patients will be treated with therapy courses of 28 days.', 'Course number 1 will be different from the followings because it will harbor radiotherapy to induce', 'self-vaccination through immunologic cell death.', 'Cyclophosphamide 50 mg tab will be given by the pharmacy to patients on day 1 each', 'course Treatment will be self-administered every day. 50 mg/day, from day 1 to day 28.', 'Avelumab 10 mg/kg will be administered in day hospital every other week.', 'Premedication: In order to mitigate infusion-related reactions, a premedication with an', 'antihistamine and with paracetamol (acetaminophen) 30 to 60 minutes prior to the first 4', 'infusions of avelumab is mandatory (for example, 25-50 mg diphenhydramine and 500-650', 'CONFRONT Study V. 1.1 del 07/05/2018 - Study Protocol', '22']['mg paracetamol IV or oral). Premedication should be administered for subsequent avelumab', 'infusions based upon clinical judgement and presence/severity of prior infusion reactions.', 'This may be modified based on local treatment standards and guidelines, as appropriate.', 'Setting: Avelumab should be administered in a setting that allows for immediate access to an', 'intensive care unit or equivalent environment and administration of therapy for anaphylaxis,', 'such as the ability to implement immediate resuscitation measures. Steroids', '(dexamethasone 10 mg), epinephrine (1:1,000 dilution), allergy medications', '(IV antihistamines), bronchodilators, or equivalents, and oxygen should be available for', 'immediate access.', 'Observation period: Following avelumab infusions, patients must be observed for 30', 'minutes post-infusion for potential infusion-related reactions.', '6.2 Study procedures and Safety assessments', '6.2.1 BEFORE TREATMENT (baseline)', 'Complete medical history, ECOG PS, physical examination (including height, weight), vital', 'signs', 'Electrocardiogram', 'Within 14 days before treatment start complete blood count and differential, blood', 'chemistry: bilirubin, AST, ALT, Alkaline phosphatase, LDH, clearance creatinine', '(Cockroft-Gault), electrolytes (Na, K. Mg, Ca), GGT, pregnancy test if clinically indicated,', 'Protrombine Time, Activated Partial Thromboplastin Time (APTT), C Reactive Protein', '(CRP), Erythrocyte Sedimentation rate (ESR), B and C hepatitis markers (if not yet known)', 'Free T4 and TSH', 'Neck CT scan or MRI within 28 days', 'Chest and abdomen CT scan within 28 days', 'Soft tissue ultrasound, bone scan, brain MRI or CT scan if clinically indicated, within 28', 'days from enrollment.', 'EORTC QLQ-C30 and QLQ-H&N35 questionnaires', 'Written informed consent', 'CONFRONT Study V. 1.1 del 07/05/2018 - Study Protocol', '23']\n\n###\n\n", "completion": "END"}